IVI Europe Regional Office
In order to facilitate expanded engagement with stakeholders in Europe and increase access to European talent and R&D funding sources, IVI sought to establish a significant presence in Europe.
In 2021, IVI opened a proposal for the establishment of the IVI Europe Regional Office (IERO) and received offers to host the IERO from Austria, France, and Sweden. After a review of the proposals, the IVI Board of Trustees accepted the offer proposed by Sweden’s Ministry of Foreign Affairs and selected Stockholm as the future location of the IERO.
On May 18, 2022 the Parliament of Sweden approved a Host Country Agreement between Sweden and the International Vaccine Institute, allowing from the establishment of the IERO.
IERO operations began on September 1st, 2022.
The establishment and operation of the IERO is made possible by Swedish funding support of 250 million SEK over 5 years.
As IVI’s first regional office outside of its headquarters in Seoul, Republic of Korea, this new presence in Sweden will bolster the life science and global health networks in Sweden and Europe, creating joint opportunities with research centers, academia, industry, and governments to advance vaccine R&D for neglected and emerging infectious diseases. IERO will also enable more effective engagement with collaborators in Africa, where IVI has helped build an extensive network of disease surveillance and clinical trial sites.
“Sweden is excited to host IVI’s new Europe Regional Office. Vaccines save lives, and in order to do that we need to bring together academia, business and public agencies, and I am happy Stockholm will now be a hub for that.”
Ms. Matilda Ernkrans, Minister for International Development Cooperation
Address & Contact Details
IVI European Regional Office
7A Posthuset, 6th Floor
Vasagatan 28, 111 20 Stockholm,
Point of Contact: email@example.com